RTP Mobile Logo
Cases from the Community: Clinical Investigators Provide Perspectives on Actual Patients with Pancreatic Cancer
Released March 2019

Faculty presentations from a CME symposium held at the 2019 Gastrointestinal Cancers Symposium. Featuring perspectives from Drs Andrew E Hendifar, Eileen M O’Reilly, Philip A Philip and Margaret A Tempero. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of pancreatic cancer.

    Pancreatic cancer is the fourth most common cause of cancer-related death among men and women in the United States. The overwhelming majority of pancreatic cancers (approximately 90%) are ductal adenocarcinomas. Unfortunately, many patients diagnosed with pancreatic adenocarcinoma (PAD) do not exhibit disease-specific symptoms until the cancer has reached an advanced stage, and for all stages of PAD the combined 1-year survival rate for patients who do not receive surgery is approximately 29% and the 5-year rate is just 7%. Published clinical trial results have led to the emergence of new therapeutic targets and regimens, and the poor clinical course for many patients with progressive PAD mandates the investigation of even more new approaches. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well informed of these advances.

    These video slide presentations from a CME symposium held during the 2019 Gastrointestinal Cancers Symposium feature presentations given by leading pancreatic cancer investigators. By providing information on important new developments, this activity will address the most pressing educational needs of practitioners involved in the management of pancreatic cancer.


    • Develop an evidence-based strategy for the treatment of resectable or borderline resectable PAD, exploring the role of neoadjuvant and adjuvant chemotherapy and/or radiation therapy.
    • Appraise available and emerging clinical trial data documenting the utility of contemporary combination chemotherapy regimens (eg, FOLFIRINOX, nab paclitaxel/gemcitabine) in the neoadjuvant and adjuvant settings, and determine what role, if any, these strategies should play in the current care of patients diagnosed with resectable PAD.
    • Consider patient- and disease-specific characteristics and available clinical trial data in the selection and sequencing of systemic therapy for locally advanced or metastatic PAD.
    • Design and implement a plan of care to recognize and manage side effects and toxicities associated with the use of approved systemic regimens for the management of locally advanced or metastatic PAD to support quality of life and continuation of therapy.
    • Recall the biologic rationale for and available and emerging data with novel investigational agents currently in clinical testing for PAD, and, where applicable, refer eligible patients for trial participation or other expanded access programs.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Andrew E Hendifar, MD
    Medical Director, Pancreatic Cancer
    Gastrointestinal and Neuroendocrine Malignancies
    Cedars-Sinai Medical Center
    Los Angeles, California

    Advisory Committee: Ipsen Biopharmaceuticals Inc; Consulting Agreements: Ipsen Biopharmaceuticals Inc, Novartis; Contracted Research: Halozyme Inc, Ipsen Biopharmaceuticals Inc.

    Eileen M O’Reilly, MD
    Winthrop Rockefeller Chair in Medical Oncology
    Section Head, Hepatopancreaticobiliary/Neuroendocrine Cancers
    Gastrointestinal Oncology Service
    Associate Director
    David M Rubenstein Center for Pancreatic Cancer
    Attending Physician, Member
    Memorial Sloan Kettering Cancer Center
    Professor of Medicine
    Weill Cornell Medical College
    New York, New York

    Consulting Agreements: 3DMedcare, Agios Pharmaceuticals Inc, Alignmed, Amgen Inc, Antengene, Aptus Clinical, Arbutus Biopharma, ASLAN Pharmaceuticals, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene, BioLineRx, Boston Scientific Corporation, BridgeBio, Bristol-Myers Squibb Company, CARsgen Therapeutics, CASI Pharmaceuticals, Celgene Corporation, Cipla Limited, CytomX Therapeutics, Daiichi Sankyo Inc, Debiopharm Group, Delcath Systems Inc, Eisai Inc, Exelixis Inc, Genoscience Pharma, Gilead Sciences Inc, Halozyme Inc, Hengrui Therapeutics Inc, Incyte Corporation, Inovio Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Kyowa Hakko Kirin Co Ltd, LAM, Lilly, Loxo Oncology, Merck, MINAPHARM Pharmaceuticals, NewLink Genetics Corporation, Novella Clinical, Onxeo, PCI Biotech, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, PharmaCyte Biotech, Pieris Pharmaceuticals, QED Therapeutics, RedHill, Sanofi Genzyme, Servier, Silenseed Ltd, SillaJen, Sobi, Targovax, twoXAR, Vicus Therapeutics, Yakult Pharmaceutical Industry CO LTD, Yiviva; Contracted Research: Acta Biologica, Agios Pharmaceuticals Inc, Array BioPharma Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene, Bristol-Myers Squibb Company, CASI Pharmaceuticals, Celgene Corporation, Exelixis Inc, Genentech, Halozyme Inc, Incyte Corporation, Lilly, MabVax, Novartis, OncoQuest Inc, Polaris Group, Puma Biotechnology Inc, QED Therapeutics, Roche Laboratories Inc.

    Philip A Philip, MD, PhD
    Kathryn Cramer Endowed Chair in Cancer Research
    Professor of Oncology and Pharmacology
    Leader, GI and Neuroendocrine Oncology
    Vice President of Medical Affairs
    Karmanos Cancer Institute
    Wayne State University
    Detroit, Michigan

    Advisory Committee: AbbVie Inc, Biolinx, Caris Life Sciences, Celgene Corporation, Eisai Inc, Forty Seven Inc, Halozyme Inc, Ipsen Biopharmaceuticals Inc, Lexicon Pharmaceuticals Inc, Lilly, Merck, Novartis, Rafael Pharmaceuticals Inc, Taiho Oncology Inc; Consulting Agreements: AbbVie Inc, Celgene Corporation, Lilly, Merck, Rafael Pharmaceuticals Inc; Contracted Research: AAA Pharmaceutical, Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals, Biolinx, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Eisai Inc, Forty Seven Inc, Gilead Sciences Inc, Halozyme Inc, Incyte Corporation, Lilly, Merck, Novocure, QED Therapeutics, Taiho Oncology Inc, Tyme Technologies Inc; Data and Safety Monitoring Board/Committee: ASLAN Pharmaceuticals, Blueprint Medicines, Erytech Pharma, Lexicon Pharmaceuticals Inc; Speakers Bureau: Bristol-Myers Squibb Company, Celgene Corporation, Ipsen Biopharmaceuticals Inc, Merck.

    Margaret A Tempero, MD
    Director, UCSF Pancreas Center
    The Rombauer Family Distinguished Professorship in Pancreas Cancer
    Clinical and Translational Science
    Leader, Pancreas Cancer Program
    Professor of Medicine, Division of Hematology and Oncology
    University of California, San Francisco
    San Francisco, California

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Cancer Prevention Research Institute of Texas, Immunovia; Consulting Agreements: Advance Medical, Astellas Pharma Global Development Inc, BioPharm Communications, Bristol-Myers Squibb Company, Celgene Corporation, EcoR1 Capital, Merck; Contracted Research: FibroGen, Gossamer Bio, Halozyme Inc.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Celgene Corporation, Halozyme Inc and Ipsen Biopharmaceuticals Inc.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: March 2019
    Expiration date: March 2020

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):